Can Sentinel Lymph Node Biopsy Be Spared in Papillary Carcinoma of the Breast?

TitleCan Sentinel Lymph Node Biopsy Be Spared in Papillary Carcinoma of the Breast?
Publication TypeJournal Article
Year of Publication2017
AuthorsWang Y, Lu S, Graves T, Ouseph MM, Resnick MB, Yakirevich E
JournalClin Breast Cancer
Volume17
Issue2
Pagination127-133
Date Published2017 04
ISSN1938-0666
KeywordsAdult, Aged, Aged, 80 and over, Axilla, Breast Neoplasms, Carcinoma, Papillary, Female, Follow-Up Studies, Humans, Lymph Node Excision, Lymphatic Metastasis, Mastectomy, Segmental, Middle Aged, Neoplasm Recurrence, Local, Neoplasm Staging, Prognosis, Retrospective Studies, Sentinel Lymph Node, Sentinel Lymph Node Biopsy
Abstract

BACKGROUND: Papillary carcinoma (PC) of the breast represents ∼0.5% of all newly diagnosed cases of breast cancer and usually has an indolent course. The current data suggest lack of a consensus in the surgical management of this disease. Because patients can occasionally develop metastatic disease, sentinel lymph node (SLN) biopsy is often performed during surgery.

MATERIALS AND METHODS: In the present study, we retrospectively evaluated the histologic characteristics of 99 cases of PC with or without associated frank invasive carcinoma, including 43 encapsulated or intracystic PCs, 24 solid PCs, and 32 intraductal PCs, and correlated these with the incidence of nodal metastasis.

RESULTS: Of the 99 cases, 64 were tumor stage Tis (noninvasive), 5 were T1 microinvasive, 17 T1a, 5 T1b, 5 T1c, and 3 were T2. A total of 37 patients (37%) underwent axillary staging, including 31 SLN biopsies and 6 axillary dissections. Only 1 patient (2.7%) with noninvasive solid PC had evidence of nodal metastasis. Follow-up information was available for 81 patients, with a mean follow-up period of 4.9 years (range, 1-13 years). Two local recurrences, no distant metastases, and no disease-related deaths were recorded.

CONCLUSION: PC rarely involves the lymph nodes even in tumors with an associated frank invasive component, and the overall prognosis and long-term survival is excellent. We propose that evaluation of the SLN should not be routinely indicated for patients with PC treated by local control lumpectomy.

DOI10.1016/j.clbc.2016.08.009
Alternate JournalClin Breast Cancer
PubMed ID27692774
Related Faculty: 
Madhu Ouseph, M.D., Ph.D.

Pathology & Laboratory Medicine 1300 York Avenue New York, NY 10065 Phone: (212) 746-6464
Surgical Pathology: (212) 746-2700